• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Omega Fatty Acids and Lutein + Zeaxanthin did not improve cardiovascular outcomes

byGautam GadeyandJames Jiang
March 18, 2014
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Omega(w)-fatty acids + macular xanthophylls supplementation did not improve primary composite outcome of cardiovascular (CV) mortality and morbidity. 

Evidence Rating Level:  2 (Good)

Study Rundown: Several trials have investigated the effects of w-fatty acids on cardiovascular (CV) outcomes.  More recent trials seem to point towards a lack of benefit on CV mortality.  This study is a randomized clinical trial designed to examine the impact of w-fatty acids and macular xanthophylls on progression to advanced age-related macular degeneration.  As part of the trial, an ancillary study called the Cardiovascular Outcome Study (COS) was created with a factorial-designed randomized trial to evaluate the impact of w- fatty acids and macular xanthophylls on a primary composite outcome of myocardial infarction (MI), stroke, and cardiovascular death.  The investigators found no significant improvement in the primary or secondary outcomes with the use of w-fatty acids or macular xanthophylls.  The strengths of the study include the randomized placebo controlled design, high follow-up rates, and the use of rigorous adjudication.  However, readers should be aware that the study is primarily powered to detect a change in macular degeneration.  Therefore, the sample size would have been inadequate to detect significant differences in singular outcomes such as rates of myocardial infarction.  Therefore, a broader composite primary outcome had to be used.

Click to read the study, published today in JAMA Internal Medicine

Relevant Reading: n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia

RELATED REPORTS

Vitamin D3 and omega-3 fatty acid supplementation does not protect against frailty

Wellness Check: Nutrition

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

In-Depth [randomized controlled trial]: This study is an ancillary study (COS) of the Age-Related Eye Disease Study 2 (AREDS2).  Patients who met the criteria for the AREDS2 study but also had stable coronary artery disease were eligible to participate.  A total of 4203 patients were recruited at 82 centers.  They were randomized to one of four primary arms: placebo, Lutein + Zeaxanthin (Macular xanthophylls), DHA + EPA (w- fatty acids), or w- fatty acids + Macular Xanthophylls.  The median length of follow-up was 4.8 years.  There was no significant decrease in the primary outcome in either the w-fatty acid group (HR, 0.95; 95% CI, 0.78-1.17), the macular xanthophylls group (HR, 0.94; 95% CI, 0.77-1.15), or the combined w- fatty acids + macular xanthophylls group (HR, 089; 95% CI, 0.67-1.19).  The same was true for composite secondary end points as well.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: fatty acidsLuteinomega-3
Previous Post

Estimated three quarters of people with influenza are asymptomatic [Flu Watch study]

Next Post

Age-adjusted D-dimer levels may rule out pulmonary embolism [ADJUST-PE trial]

RelatedReports

Chronic Disease

Vitamin D3 and omega-3 fatty acid supplementation does not protect against frailty

October 11, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

October 6, 2022
Higher omega-3 blood levels associated with larger brain volumes
Chronic Disease

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

May 13, 2022
Galcanezumab reduces the frequency of episodic cluster headaches
Neurology

More omega-3 and less omega-6 fatty acid consumption associated with reduced migraine frequency and severity

September 3, 2021
Next Post
Lower target oxygen saturation in extremely preterm infants appears safe

Age-adjusted D-dimer levels may rule out pulmonary embolism [ADJUST-PE trial]

Low circulating cholesterol in neonates linked with pyloric stenosis

Simvastatin may slow brain atrophy in secondary progressive multiple sclerosis [MS-STAT study]

Nonleg venous thromboses associated with PE, longer ICU stay

Nonleg venous thromboses associated with PE, longer ICU stay

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.